The DOI matches its Crossref record.
Naringenin‐Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways
Abstract
Prostate cancer is the most common cancer in men and the second most common cause of cancer‐related deaths in men. Although, various drugs targeting the androgen receptor are normally used, the patients frequently undergo recurrence of the disease. To overcome these limitations, natural compounds have been researched for evidence that they suppress progression and metastasis of various cancer cells. In the present study, we investigated effects of naringenin, a natural anti‐oxidant flavonoid derived from citrus, on prostate cancer cells (PC3 and LNCaP). Results of present study with PC3 and LNCaP cells revealed that naringenin inhibited proliferation and migration, while inducing apoptosis and ROS production by those cells. In addition, naringenin‐induced loss of mitochondrial membrane potential and increased Bax and decreased Bcl‐2 proteins in PC3 cells, but not LNCaP cells. In a dose‐dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells. However, naringenin activated phosphorylation of AKT in both PC3 and LNCaP cells. Then, targeted signaling proteins associated with viability of PC3 and LNCaP cells were analyzed using pharmacological inhibitors of AKT and ERK1/2 cell signaling pathways. Moreover, we compared the apoptotic effects of naringenin and paclitaxel alone and in combination to find that naringenin enhanced the efficiency of paclitaxel to suppress progression of prostate cancer cell lines. Collectively, these results indicate that naringenin is a potential chemotherapeutic agent for treatment of prostate cancer. J. Cell. Biochem. 118: 1118–1131, 2017. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Flavonoids as Anticancer Agents
Kopustinskiene, D. M., Jakstas, V., Savickas, A., & Bernatoniene, J. (2020) · Nutrients · doi:10.3390/nu12020457 · Cited by 1,295
The Therapeutic Potential of Naringenin: A Review of Clinical Trials
Salehi, B., Fokou, P. V. T., Sharifi-Rad, M., Zucca, P., Pezzani, R., Martins, N., & Sharifi-Rad, J. (2019) · Pharmaceuticals · doi:10.3390/ph12010011 · Cited by 814
RETRACTED: Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms
Slika, H., Mansour, H., Wehbe, N., Nasser, S. A., Iratni, R., Nasrallah, G., Shaito, A., Ghaddar, T., Kobeissy, F., & Eid, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112442 · Cited by 441
RetractedNaringenin: A potential flavonoid phytochemical for cancer therapy
Motallebi, M., Bhia, M., Rajani, H. F., Bhia, I., Tabarraei, H., Mohammadkhani, N., Pereira-Silva, M., Kasaii, M. S., Nouri-Majd, S., Mueller, A.-L., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120752 · Cited by 328
Naringenin as a potential immunomodulator in therapeutics
Zeng, W., Jin, L., Zhang, F., Zhang, C., & Liang, W. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.002 · Cited by 305
Antiproliferative and palliative activity of flavonoids in colorectal cancer
Fernández, J., Silván, B., Entrialgo-Cadierno, R., Villar, C. J., Capasso, R., Uranga, J. A., Lombó, F., & Abalo, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112241 · Cited by 258
Citrus flavonoids and their antioxidant evaluation
Wang, Y., Liu, X.-J., Chen, J.-B., Cao, J.-P., Li, X., & Sun, C.-D. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1870035 · Cited by 259
Metadata
- Authors
- Lim, W., Park, S., Bazer, F. W., & Song, G.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2017-01-10
- Volume
- 118
- Issue
- 5
- Pages
- 1118-1131
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2519719294
- Cited by
- 166
- References
- 0
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.